These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19562682)

  • 21. Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.
    van Beijsterveldt L; Geerts R; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2004; 54(2):85-94. PubMed ID: 15038457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
    Friedrich C; Shi X; Zeng P; Ring A; Woerle HJ; Patel S
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):889-95. PubMed ID: 23073142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
    Eckhardt M; Langkopf E; Mark M; Tadayyon M; Thomas L; Nar H; Pfrengle W; Guth B; Lotz R; Sieger P; Fuchs H; Himmelsbach F
    J Med Chem; 2007 Dec; 50(26):6450-3. PubMed ID: 18052023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.
    Thomas L; Tadayyon M; Mark M
    J Pharmacol Exp Ther; 2009 Feb; 328(2):556-63. PubMed ID: 18971371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
    He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
    Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo.
    Ono C; Yamada M; Tanaka M
    J Pharm Pharmacol; 2003 Dec; 55(12):1647-54. PubMed ID: 14738591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys.
    Kuhlmann O; Paehler A; Weick I; Funk C; Pantze M; Zell M; Timm U
    Xenobiotica; 2010 Dec; 40(12):840-52. PubMed ID: 20868265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.